|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/04/24 Astria Therapeutics, Inc. 10-K 12/31/23 80:11M Toppan Merrill/FA2 |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 2.19M
2: EX-10.18 Material Contract HTML 434K
3: EX-10.19 Material Contract HTML 1.58M
4: EX-21.1 Subsidiaries List HTML 23K
5: EX-23.1 Consent of Expert or Counsel HTML 22K
10: EX-97.1 Clawback Policy re: Recovery of Erroneously HTML 41K
Awarded Compensation
6: EX-31.1 Certification -- §302 - SOA'02 HTML 27K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 27K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 24K
9: EX-32.2 Certification -- §906 - SOA'02 HTML 24K
16: R1 Document and Entity Information HTML 93K
17: R2 Consolidated Balance Sheets HTML 110K
18: R3 Consolidated Balance Sheets (Parenthetical) HTML 46K
19: R4 Consolidated Statements of Operations HTML 72K
20: R5 Consolidated Statements of Comprehensive Loss HTML 45K
21: R6 Consolidated Statements Comprehensive Loss HTML 24K
(Parenthetical)
22: R7 Consolidated Statements of Stockholders' Equity HTML 85K
23: R8 Consolidated Statements of Cash Flows HTML 94K
24: R9 Organization and Operations HTML 36K
25: R10 Summary of Significant Accounting Policies HTML 96K
26: R11 Fair Value Measurements HTML 107K
27: R12 Short-Term Investments HTML 76K
28: R13 Accrued Expenses HTML 40K
29: R14 Commitments HTML 33K
30: R15 Stockholders' Equity HTML 63K
31: R16 Stock Incentive Plans HTML 82K
32: R17 Income Taxes HTML 80K
33: R18 Defined Contribution Benefit Plan HTML 25K
34: R19 Subsequent Events HTML 28K
35: R20 Summary of Significant Accounting Polices HTML 145K
(Polices)
36: R21 Summary of Significant Accounting Policies HTML 59K
(Tables)
37: R22 Fair Value Measurements (Tables) HTML 105K
38: R23 Short-Term Investments (Tables) HTML 73K
39: R24 Accrued Expenses (Tables) HTML 40K
40: R25 Commitments (Tables) HTML 31K
41: R26 Stockholders' Equity (Tables) HTML 61K
42: R27 Stock Incentive Plans (Tables) HTML 73K
43: R28 Income Taxes (Tables) HTML 73K
44: R29 Organization and Operations - December 2022 HTML 40K
Financing (Details)
45: R30 Organization and Operations - License Agreement HTML 41K
(Details)
46: R31 Organization and Operations - October 2023 HTML 44K
Financing (Details)
47: R32 Organization and Operations - Liquidity (Details) HTML 59K
48: R33 Summary of Significant Accounting Polices - Cash HTML 34K
and Cash Equivalents and Restricted Cash (Details)
49: R34 Summary of Significant Accounting Polices - Fair HTML 33K
Value of Financial Instruments (Details)
50: R35 Summary of Significant Accounting Policies - HTML 31K
Stock-Based Compensation (Details)
51: R36 Summary of Significant Accounting Policies - Net HTML 39K
Loss Per Share (Details)
52: R37 Summary of Significant Accounting Policies - HTML 24K
Segment Information (Details)
53: R38 Summary of Significant Accounting Policies - HTML 33K
Preferred Stock Discount (Details)
54: R39 Summary of Significant Accounting Policies - HTML 24K
Financing Costs (Details)
55: R40 Summary of Significant Accounting Policies - HTML 31K
License Agreement (Details)
56: R41 Fair Value Measurements - Fair value hierarchy HTML 58K
(Details)
57: R42 Fair Value Measurements - Warrant liability HTML 28K
(Details)
58: R43 Short-Term Investments (Details) HTML 50K
59: R44 Accrued Expenses (Details) HTML 34K
60: R45 Commitments (Details) HTML 36K
61: R46 Stockholders' Equity - Preferred Stock (Details) HTML 39K
62: R47 Stockholders' Equity - Common Stock Outstanding HTML 36K
Warrants (Details)
63: R48 Stockholders' Equity - Common Stock (Details) HTML 32K
64: R49 Stockholders' Equity - Shares Reserved for Future HTML 40K
Issuance (Details)
65: R50 Stock Incentive Plans - Summary of Plans (Details) HTML 38K
66: R51 Stock Incentive Plans - Stock option activity HTML 94K
(Details)
67: R52 Stock Incentive Plans - Stock-Based Compensation HTML 37K
Expense (Details)
68: R53 Stock Incentive Plans - Inducement plan (Details) HTML 48K
69: R54 Income Taxes - Reconciliation (Details) HTML 42K
70: R55 Income Taxes - Deferred tax assets (Details) HTML 53K
71: R56 Income Taxes - Operating Loss Carryforwards HTML 34K
(Details)
72: R57 Defined Contribution Benefit Plan (Details) HTML 25K
73: R58 Subsequent Events (Details) HTML 44K
74: R59 Pay vs Performance Disclosure HTML 34K
75: R60 Insider Trading Arrangements HTML 28K
77: XML IDEA XML File -- Filing Summary XML 133K
80: XML XBRL Instance -- atxs-20231231x10k_htm XML 1.50M
76: EXCEL IDEA Workbook of Financial Report Info XLSX 125K
12: EX-101.CAL XBRL Calculations -- atxs-20231231_cal XML 135K
13: EX-101.DEF XBRL Definitions -- atxs-20231231_def XML 536K
14: EX-101.LAB XBRL Labels -- atxs-20231231_lab XML 1.13M
15: EX-101.PRE XBRL Presentations -- atxs-20231231_pre XML 819K
11: EX-101.SCH XBRL Schema -- atxs-20231231 XSD 148K
78: JSON XBRL Instance as JSON Data -- MetaLinks 456± 679K
79: ZIP XBRL Zipped Folder -- 0001410578-24-000127-xbrl Zip 727K
Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with this Annual Report on Form 10-K of Astria Therapeutics, Inc. (the “Company”) for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Noah C. Clauser, Chief Financial Officer and Treasurer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that, to his knowledge on the date hereof:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| |
Date: March 4, 2024 | |
| /s/ Noah C. Clauser |
| |
| Chief Financial Officer and Treasurer |
| (Principal Financial Officer) |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/4/24 | None on these Dates | ||
| For Period end: | 12/31/23 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/09/24 Astria Therapeutics, Inc. 10-Q 3/31/24 56:4.8M Toppan Merrill/FA2 3/04/24 Astria Therapeutics, Inc. 424B5 1:348K Toppan Merrill/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 12/20/23 Astria Therapeutics, Inc. 8-K:5,9 12/14/23 11:279K Toppan Merrill/FA 10/12/23 Astria Therapeutics, Inc. 8-K:1,8,9 10/11/23 15:775K Toppan Merrill/FA 8/07/23 Astria Therapeutics, Inc. 10-Q 6/30/23 56:5.2M Toppan Merrill/FA2 6/06/23 Astria Therapeutics, Inc. 8-K:5,9 6/02/23 12:584K Toppan Merrill/FA 5/12/22 Astria Therapeutics, Inc. 10-Q 3/31/22 66:5.6M Toppan Merrill/FA 3/10/22 Astria Therapeutics, Inc. 10-K 12/31/21 78:12M Toppan Merrill/FA 2/22/22 Astria Therapeutics, Inc. 8-K:5,9 2/17/22 12:339K Toppan Merrill/FA 3/11/21 Astria Therapeutics, Inc. S-8 3/11/21 4:173K Toppan Merrill/FA 3/11/21 Astria Therapeutics, Inc. 10-K 12/31/20 10:1.8M Toppan Merrill/FA 1/29/21 Astria Therapeutics, Inc. 8-K:1,2,3,5 1/28/21 7:5.8M Toppan Merrill/FA 5/13/15 Astria Therapeutics, Inc. S-1 24:8M Toppan Merrill-FA |